Fresenius Medical Care responds to kidney plan. Fresenius Medical Care stock falls 2.06 percent.
Published on 10/21/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly comparison and policy date
- Fresenius Medical Care welcomed the kidney plan with three policy priorities on October 20, 2026.
- Second-quarter revenue reached EUR 4.86 billion versus EUR 4.79 billion in the prior year.
- Fresenius Medical Care stock trades at EUR 38.55 at 10:47 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.06 percent below the Xetra close of October 20, 2026.
Fresenius Medical Care (ISIN DE0005785802) was trading at EUR 38.55 at Lang & Schwarz on October 21, 2026, at 10:47 a.m. CEST, down 2.06 percent from the Xetra close of October 20, 2026 at EUR 39.36. The company welcomed the United States Kidney Care National Plan released on October 20, 2026, according to WN.
Three dates define the transition
On October 7, 2026, Fresenius Medical Care appointed Shervin J. Korangy, 51, as CEO effective October 12, 2026. On October 20, 2026, the HHS plan set three priorities for kidney care: prevention, dialysis choice and transplantation, according to HHS. On October 20, 2026, FMC responded to that plan, while the stock stood at EUR 39.36 at the Xetra close.
What does the plan mean for dialysis?
The policy direction could matter because FMC provides kidney care and dialysis services, while the plan explicitly seeks greater choice and fewer barriers to innovation. The company is entering that discussion after second-quarter revenue of EUR 4.86 billion, compared with EUR 4.79 billion in the prior-year quarter, while net profit was EUR 218 million versus EUR 225.27 million, according to Markets Insider.
Analyst caution remains visible. On October 19, 2026, Deutsche Bank Research maintained a Hold rating and a EUR 40.00 target, according to MarketScreener. That target is 3.76 percent above the Lang & Schwarz price, leaving the November results as the next test of the operating narrative.
Results arrive on November 3
Fresenius Medical Care's investor calendar schedules third-quarter 2026 results for November 3, 2026, followed by the quarterly financial report on November 6, 2026, according to the company's investor calendar.
Stock stays below the target
The stock was trading at EUR 38.55 at Lang & Schwarz on October 21, 2026, at 10:47 a.m. CEST, 2.06 percent below the Xetra close of October 20, 2026 at EUR 39.36. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.
FMC stock facts
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 21, 2026, 10:47 a.m. CEST): EUR 38.55
- Change versus Xetra close: minus 2.06 percent
- Xetra close (October 20, 2026): EUR 39.36
- Sector / Industry: Health Care / Health Care Providers
Market context: Market report DAX.
